Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (4323)	5/18/1998 3:43:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 6136

To All, Well I added more to my position on the weakness today so AGPH is now my largest holding. Man is this thing a bargain. It's being penalized for being a one drug company when most biotechs are no drug companies. Of course everyone one here knows that, but it bears repeating. People are afraid of competition lurking out there somewhere. Well for sure Viracept is not subject to any more potential competition than any other number 1 in it's class drug. Another way I look at it is compared to XYZ Hi-Tech company with a top selling product the solidity of market share for Viracept is most excellent. If it goes down another point I'm selling something else and buying more AGPH. It's the best bargain with tremendous growth potential I see in an overpriced market by a mile.

To: PAL who wrote (4323)	5/18/1998 4:42:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

No, Ms Wang does not carry much if any weight. Her reports never move the stock that I have seen. She and/or her company have maintained a 65-70 12-month price target going back to mid '96 I believe. I guess the logic is that if you maintain a price target long enough, sooner or later it may get there. Doug Lind who used to work for PaineWebber seems to have some influence though. He moved to a new house, I believe Morgan Stanley. His 12-month target is $51 if memory serves. I believe the unrelenting stream of insider selling doesn't help. A couple of open market insider buys would really boost confidence...probably take us over $40. I sometimes wonder why they don't do this, even if confidence is low...many investors specifically follow insider buys. sf